A DEA inspection of a pharmacy can begin with a single knock and a Notice of Inspection form, no advance warning required. The registrant that has already reconciled its own controlled substance records, before an investigator opens the biennial inventory or asks a technician a question, walks into that inspection from a position of control rather than reaction. The registrant that waits until the inspector is standing at the counter to find a discrepancy is negotiating from behind. Preparing for a DEA inspection is largely a matter of self-audit: verifying the records DEA will ask for, training staff on how to conduct themselves once the inspection begins, and closing gaps before they surface as findings.
The Self-Audit Before the Inspector Arrives
The starting point is the biennial inventory required under 21 CFR 1304.11: an exact count of Schedule I and Schedule II stock and an estimated count for Schedules III through V, taken at least once every two years and kept at the registered location. A pharmacy that treats the count as a once-every-two-years task, rather than a working inventory reconciliation tool, is the pharmacy most likely to be surprised by a discrepancy during an inspection. DEA already holds a transaction-level record of what a pharmacy received, because distributors and manufacturers report every acquisition to the Automation of Reports and Consolidated Orders System (ARCOS). A pharmacy that orders Schedule II drugs through the Controlled Substances Ordering System should reconcile its own electronic order history against what was actually received and dispensed before an inspector runs that same comparison. Building and maintaining the underlying file, invoices, executed order forms, and the perpetual inventory, is its own discipline, covered in our companion piece on DEA recordkeeping and audit readiness.
Preparing Staff for an Unannounced Inspection
DEA conducts unannounced inspections of retail pharmacies, and absent a warrant, the inspection proceeds only with the registrant's informed consent. An investigator presents DEA Form 82, the notice of inspection, and the pharmacist-in-charge or another person with authority to act for the pharmacy decides whether to sign that consent. If consent is refused, DEA can seek an administrative inspection warrant from a magistrate, a standard that turns on the public interest in enforcement rather than criminal probable cause. Staff should know, before an inspector ever arrives, who is authorized to sign the consent form, who gets called immediately once an inspection begins, and that no one on the floor is required to answer questions about specific dispensing decisions before counsel is involved. A staff member who has never rehearsed that sequence is the one most likely to make an unscripted statement that becomes part of the inspection record.
Correcting Deficiencies Before They Become Findings
Retail pharmacies are not generally subject to the suspicious order monitoring obligations that 21 CFR 1301.74(b) imposes on distributors, but a pharmacy that also functions as a distributor within a chain, through central fill or inter-store transfers, should confirm that monitoring program is documented and current before an inspection, not after. The same self-audit logic applies to any gap a pharmacy finds on its own: a missing invoice, a stale power of attorney for controlled substance orders, a discrepancy between the physical count and the perpetual inventory. A pharmacy that identifies and corrects a deficiency on its own initiative, with a documented explanation and a dated correction, is in a materially different position than a pharmacy where DEA finds the same gap first. Left uncorrected, a pattern of recordkeeping deficiencies is the fact pattern DEA cites when it moves from an inspection finding toward an order to show cause.
A deficiency a pharmacy finds and corrects on its own is a compliance record. The same deficiency, found first by a DEA investigator, is the start of an inspection finding.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel before a self-audit reveals a deficiency, or immediately upon receiving DEA inspection findings. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to DEA's requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with DEA on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of the matter and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance defends pharmacies in DEA inspections, registration matters, and orders to show cause nationwide. Our bench includes a former federal prosecutor and a former senior pharmacy benefit manager executive, background that shapes how we structure a pre-inspection self-audit and how we respond once an inspection is already underway. If your pharmacy wants to review its controlled substance records, staff protocols, or an open deficiency before DEA arrives, contact us for a free, confidential consultation.
